Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine A2A Receptor Occupancy in LRRK2 Carriers
NCT05009199Phase 1Completed
- Sponsor
- Invicro
- Start
- Jun 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of caffeine in Parkinson's disease (PD), sponsored by Invicro. Primary endpoints: Pharmacodynamics of multiple doses of oral caffeine on striatal binding of the adenosine A2A receptor ligand [18F]MNI-444 at 1 year and Pharmacokinetics of multiple doses of oral caffeine at 1 year. Started Jun 2021; status: completed.
02
Drugs
caffeine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05009199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009199.